Primary tumor location impacts survival in colorectal cancer patients after primary resection: a population-based propensity score matching cohort study

被引:3
作者
Yin, Haipeng [1 ]
Li, He [1 ]
Xu, Jian [1 ,2 ]
Wu, Ju [1 ,2 ]
机构
[1] Dalian Univ, Affiliated Zhongshan Hosp, Dept Hepatobiliary Surg, Dalian, Peoples R China
[2] Dalian Univ, Affiliated Zhongshan Hosp, 6 Jiefang St, Dalian 116001, Liaoning, Peoples R China
关键词
Colorectal cancer; primary resection; tumor location; LIVER METASTASES; CHEMOTHERAPY; MUTATIONS; DISTAL; STAGE; SITE; KRAS; BRAF;
D O I
10.21037/jgo-23-71
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Right-sided colon cancers (R-CCs) are associated with worse outcomes compared to left sided colon cancers (L-CCs). This study aimed to investigate whether a difference in survival existed among R-CC, L-CC, and rectal cancer (ReC) and subsequent liver metastasis. Methods: Data from the Surveillance, Epidemiology, and End Results (SEER) database for 2010-2015 was used to identify colorectal cancer (CRC) patients who underwent surgical resection of primary disease. Propensity score adjustment and Cox regression models were used to identify risk factors and prognostic factors of primary tumor location (PTL). Kaplan-Meier curve analysis and the log-rank test were used to evaluate overall survival (OS) of CRC patients. Results: Our results showed that among the 73,350 included patients, 49% were R-CC, 27.6% L-CC, and 23.1% ReC. Before propensity score matching (PSM), the OS of the R-CC group was significantly lower than that of the L-CC and ReC groups (P<0.05). However, the clinicopathological characteristics, including gender, tumor grade, tumor size, marital status, tumor (T) stage, node (N) stage, and carcinoembryonic antigen (CEA), were significantly unbalanced among the 3 groups (P<0.05). After 1:1 PSM, 8670 patients were effectively screened out in each group. The differences in clinicopathological characteristics among the 3 groups were significantly reduced, and baseline distribution characteristics such as gender, tumor size, and CEA were significantly improved after matching (P>0.05). Survival was higher in the left-side group when evaluated by tumor sidedness, and ReC patients had the highest median survival (114.3 months). Right-sided cancer patients had the worst prognosis in both PTL and sidedness analyses, with a median survival of 76.6 months. Among CRC patients with synchronous liver metastases, adjustment by inverse propensity weight and propensity score and analysis of OS yielded similar results and had more significant stratification results. Conclusions: In conclusion, R-CC has a worse survival prognosis compared to L-CC and ReC, and they are fundamentally different tumors that have distinct effects on CRC patients with liver metastases.
引用
收藏
页码:886 / 899
页数:14
相关论文
共 51 条
  • [1] American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
    Allegra, Carmen J.
    Jessup, J. Milburn
    Somerfield, Mark R.
    Hamilton, Stanley R.
    Hammond, Elizabeth H.
    Hayes, Daniel F.
    McAllister, Pamela K.
    Morton, Roscoe F.
    Schilsky, Richard L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) : 2091 - 2096
  • [2] Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
    Arnold, D.
    Lueza, B.
    Douillard, J. -Y.
    Peeters, M.
    Lenz, H. -J.
    Venook, A.
    Heinemann, V.
    Van Cutsem, E.
    Pignon, J. -P.
    Tabernero, J.
    Cervantes, A.
    Ciardiello, F.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (08) : 1713 - 1729
  • [3] Austin PC, 2008, STAT MED, V27, P2037, DOI 10.1002/sim.3150
  • [4] Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale
    Bagri, Anil
    Kouros-Mehr, Hosein
    Leong, Kevin G.
    Plowman, Greg D.
    [J]. TRENDS IN MOLECULAR MEDICINE, 2010, 16 (03) : 122 - 132
  • [5] Benhattar J, 1996, INT J CANCER, V69, P190, DOI 10.1002/(SICI)1097-0215(19960621)69:3<190::AID-IJC7>3.0.CO
  • [6] 2-V
  • [7] Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review
    Biller, Leah H.
    Schrag, Deborah
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (07): : 669 - 685
  • [8] Surgery in asymptomatic patients with colorectal cancer and unresectable liver metastases: the authors' experience
    Boselli, Carlo
    Renzi, Claudio
    Gemini, Alessandro
    Castellani, Elisa
    Trastulli, Stefano
    Desiderio, Jacopo
    Corsi, Alessia
    Barberini, Francesco
    Cirocchi, Roberto
    Santoro, Alberto
    Parisi, Amilcare
    Redler, Adriano
    Noya, Giuseppe
    [J]. ONCOTARGETS AND THERAPY, 2013, 6 : 267 - 272
  • [9] The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival
    Brouwer, Nelleke P. M.
    Van der Kruijssen, Dave E. W.
    Hugen, Niek
    de Hingh, Ignace H. J. T.
    Nagtegaal, Iris D.
    Verhoeven, Rob H. A.
    Koopman, Miriam
    de Wilt, Johannes H. W.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (05) : 1580 - 1588
  • [10] COLORECTAL-CANCER - EVIDENCE FOR DISTINCT GENETIC CATEGORIES BASED ON PROXIMAL OR DISTAL TUMOR LOCATION
    BUFILL, JA
    [J]. ANNALS OF INTERNAL MEDICINE, 1990, 113 (10) : 779 - 788